T1	Modifier 63 94	locoregional oral squamous cell
E1	Modifier:T1
T2	Condition 95 104	carcinoma
E2	Condition:T2
T3	Condition 106 110	OSCC
E3	Condition:T3 Name:T54
T4	Negation 112 119	without
E4	Negation:T4
T5	Modifier 132 139	distant
E5	Modifier:T5
T6	Condition 140 150	metastases
E6	Condition:T6 Name:T55
T7	Condition 152 156	OSCC
E7	Condition:T7
T8	Modifier 170 193	subsites of oral tongue
E8	Modifier:T8
T9	Modifier 195 209	floor of mouth
E9	Modifier:T9
T10	Modifier 211 218	gingiva
E10	Modifier:T10
T11	Modifier 220 238	retromolar trigone
E11	Modifier:T11
T12	Or 239 242	and
E12	Or:T12
T13	Modifier 243 256	buccal mucosa
E13	Modifier:T13
T14	Or 257 259	OR
E14	Or:T14
T15	Modifier 260 269	Recurrent
E15	Modifier:T15
T16	Or 270 272	or
E16	Or:T16
T17	Modifier 273 283	persistent
E17	Modifier:T17
T18	Modifier 306 318	locoregional
E18	Modifier:T18
T19	Condition 319 323	OSCC
E19	Condition:T19
T20	Eq-Comparison 333 342	initially
E20	Eq-Comparison:T20
T21	Procedure 343 350	treated
E21	Procedure:T21
T22	Procedure 356 363	surgery
E22	Procedure:T22 Name:T59
T23	Assertion 384 396	eligible for
E23	Assertion:T23
A1	Assertion-Type-Value E23 hypothetical
T24	Procedure 397 415	surgical resection
E24	Procedure:T24 Name:T60
T25	Eq-Comparison 421 442	greater than 18 years
E25	Eq-Comparison:T25 Operator:T61 Value:T62 Temporal-Unit:T63
T26	Age 446 449	age
E26	Age:T26
T27	Eq-Comparison 475 480	prior
E27	Eq-Comparison:T27 Temporal-Period:T64
T28	Procedure 481 494	immunotherapy
E28	Procedure:T28 Name:T65
T29	Or 495 497	or
E29	Or:T29
T30	Procedure 498 507	treatment
E30	Procedure:T30
T31	Other 513 520	another
E31	Other:T31
T32	Drug 521 536	anti PD-1 agent
E32	Drug:T32 Name:T66
T33	Drug 545 554	nivolumab
E33	Drug:T33 Name:T67
T34	Eq-Comparison 560 565	prior
E34	Eq-Comparison:T34 Temporal-Period:T68
T35	Procedure 566 578	chemotherapy
E35	Procedure:T35 Name:T69
T36	Drug 589 598	cetuximab
E36	Drug:T36
T37	Or 599 601	or
E37	Or:T37
T38	Procedure 602 619	radiation therapy
E38	Procedure:T38 Name:T71
T39	Condition 625 649	concomitant malignancies
E39	Condition:T39
T40	Exception 650 656	except
E40	Exception:T40
T41	Modifier 657 680	cutaneous squamous cell
E41	Modifier:T41
T42	Condition 681 690	carcinoma
E42	Condition:T42
T43	Or 691 693	or
E43	Or:T43
T44	Modifier 694 704	basal cell
E44	Modifier:T44
T45	Condition 705 714	carcinoma
E45	Condition:T45
T46	Modifier 720 740	unresectable primary
E46	Modifier:T46
T47	Condition 741 746	tumor
E47	Condition:T47 Name:T74
T48	Or 747 749	or
E48	Or:T48
T49	Condition 750 766	regional disease
E49	Condition:T49 Name:T75
T50	Or 767 769	or
E50	Or:T50
T51	Modifier 770 777	distant
E51	Modifier:T51
T52	Condition 778 788	metastases
E52	Condition:T52 Name:T76
T53	Condition-Name 81 104	squamous cell carcinoma
T54	Condition-Name 106 110	OSCC
T55	Condition-Name 140 150	metastases
T56	Condition-Name 182 193	oral tongue
T57	Condition-Name 243 256	buccal mucosa
T58	Condition-Name 306 323	locoregional OSCC
T59	Procedure-Name 356 363	surgery
T60	Procedure-Name 397 415	surgical resection
T61	Eq-Operator 421 433	greater than
A2	Eq-Operator-Value T61 GT
T62	Eq-Value 434 436	18
T63	Eq-Temporal-Unit 437 442	years
A3	Eq-Temporal-Unit-Value T63 year
T64	Eq-Temporal-Period 475 480	prior
A4	Eq-Temporal-Period-Value T64 past
T65	Procedure-Name 481 494	immunotherapy
T66	Drug-Name 521 536	anti PD-1 agent
T67	Drug-Name 545 554	nivolumab
T68	Eq-Temporal-Period 560 565	prior
A5	Eq-Temporal-Period-Value T68 past
T69	Procedure-Name 566 578	chemotherapy
T70	Procedure-Name 589 598	cetuximab
T71	Procedure-Name 602 619	radiation therapy
T72	Condition-Name 667 690	squamous cell carcinoma
T73	Condition-Name 694 714	basal cell carcinoma
T74	Condition-Name 741 746	tumor
T75	Condition-Name 750 766	regional disease
T76	Condition-Name 778 788	metastases